VAD chemotherapy as remission induction for multiple myeloma.
A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033610/ https://www.ncbi.nlm.nih.gov/pubmed/7841049 |
_version_ | 1782136875104862208 |
---|---|
author | Anderson, H. Scarffe, J. H. Ranson, M. Young, R. Wieringa, G. S. Morgenstern, G. R. Fitzsimmons, L. Ryder, D. |
author_facet | Anderson, H. Scarffe, J. H. Ranson, M. Young, R. Wieringa, G. S. Morgenstern, G. R. Fitzsimmons, L. Ryder, D. |
author_sort | Anderson, H. |
collection | PubMed |
description | A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In addition, oral dexamethasone 40 mg day-1 was given for 4 days. Intermittent dexamethasone was only given to 19 patients. Courses were repeated every 21 days. The overall response rate was 84% [27% complete response (CR)] in previously untreated patients and 61% (3% CR) in patients with relapsed and refractory disease. The median survival was 36 months for untreated patients and 10 months for those who had received prior therapy. VAD was well tolerated; however, despite prophylaxis, 54% patients received antibiotics at some time during therapy and 37% had dyspepsia. Twenty-three patients subsequently received a transplant (eight allografts, eight marrow autografts and seven peripheral blood stem cell transplants). Eight have died-four in the allogeneic group and four in the autologous group. The overall median survival of transplanted patients has not yet been reached. VAD is an effective, out-patient therapy for inducing remission in multiple myeloma. Post-remission therapy needs to be optimised, but it is likely that the needs of previously untreated patients may be different from those with relapsed and refractory disease. |
format | Text |
id | pubmed-2033610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1995 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20336102009-09-10 VAD chemotherapy as remission induction for multiple myeloma. Anderson, H. Scarffe, J. H. Ranson, M. Young, R. Wieringa, G. S. Morgenstern, G. R. Fitzsimmons, L. Ryder, D. Br J Cancer Research Article A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In addition, oral dexamethasone 40 mg day-1 was given for 4 days. Intermittent dexamethasone was only given to 19 patients. Courses were repeated every 21 days. The overall response rate was 84% [27% complete response (CR)] in previously untreated patients and 61% (3% CR) in patients with relapsed and refractory disease. The median survival was 36 months for untreated patients and 10 months for those who had received prior therapy. VAD was well tolerated; however, despite prophylaxis, 54% patients received antibiotics at some time during therapy and 37% had dyspepsia. Twenty-three patients subsequently received a transplant (eight allografts, eight marrow autografts and seven peripheral blood stem cell transplants). Eight have died-four in the allogeneic group and four in the autologous group. The overall median survival of transplanted patients has not yet been reached. VAD is an effective, out-patient therapy for inducing remission in multiple myeloma. Post-remission therapy needs to be optimised, but it is likely that the needs of previously untreated patients may be different from those with relapsed and refractory disease. Nature Publishing Group 1995-02 /pmc/articles/PMC2033610/ /pubmed/7841049 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Anderson, H. Scarffe, J. H. Ranson, M. Young, R. Wieringa, G. S. Morgenstern, G. R. Fitzsimmons, L. Ryder, D. VAD chemotherapy as remission induction for multiple myeloma. |
title | VAD chemotherapy as remission induction for multiple myeloma. |
title_full | VAD chemotherapy as remission induction for multiple myeloma. |
title_fullStr | VAD chemotherapy as remission induction for multiple myeloma. |
title_full_unstemmed | VAD chemotherapy as remission induction for multiple myeloma. |
title_short | VAD chemotherapy as remission induction for multiple myeloma. |
title_sort | vad chemotherapy as remission induction for multiple myeloma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033610/ https://www.ncbi.nlm.nih.gov/pubmed/7841049 |
work_keys_str_mv | AT andersonh vadchemotherapyasremissioninductionformultiplemyeloma AT scarffejh vadchemotherapyasremissioninductionformultiplemyeloma AT ransonm vadchemotherapyasremissioninductionformultiplemyeloma AT youngr vadchemotherapyasremissioninductionformultiplemyeloma AT wieringags vadchemotherapyasremissioninductionformultiplemyeloma AT morgensterngr vadchemotherapyasremissioninductionformultiplemyeloma AT fitzsimmonsl vadchemotherapyasremissioninductionformultiplemyeloma AT ryderd vadchemotherapyasremissioninductionformultiplemyeloma |